Articoli con mandati relativi all'accesso pubblico - Michele CavoUlteriori informazioni
Non disponibili pubblicamente: 15
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind …
SK Kumar, SJ Harrison, M Cavo, J de la Rubia, R Popat, C Gasparetto, ...
The Lancet Oncology 21 (12), 1630-1642, 2020
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 …
MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ...
The Lancet Oncology 22 (6), 801-812, 2021
Mandati: Government of Spain
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L Melchor, A Brioli, CP Wardell, A Murison, NE Potter, MF Kaiser, ...
Leukemia 28 (8), 1705-1715, 2014
Mandati: US National Institutes of Health, German Research Foundation, Cancer Research UK
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients
A Curti, L Ruggeri, S Parisi, A Bontadini, E Dan, MR Motta, S Rizzi, ...
Clinical Cancer Research 22 (8), 1914-1921, 2016
Mandati: Governo Italiano
Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
E Zamagni, C Nanni, L Dozza, T Carlier, C Bailly, P Tacchetti, A Versari, ...
Journal of Clinical Oncology 39 (2), 116-125, 2021
Mandati: Agence Nationale de la Recherche
Consolidation and maintenance in newly diagnosed multiple myeloma
P Sonneveld, MA Dimopoulos, M Beksac, B van der Holt, S Aquino, ...
Journal of Clinical Oncology 39 (32), 3613-3622, 2021
Mandati: Dutch Cancer Society
FOXM1 transcription factor: a new component of chronic myeloid leukemia stem cell proliferation advantage
M Mancini, F Castagnetti, S Soverini, E Leo, C De Benedittis, G Gugliotta, ...
Journal of Cellular Biochemistry 118 (11), 3968-3975, 2017
Mandati: Governo Italiano
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
F Palandri, L Catani, M Bonifacio, G Benevolo, F Heidel, GA Palumbo, ...
British Journal of Haematology 183 (1), 35-46, 2018
Mandati: European Commission
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with …
EA Martino, C Conticello, E Zamagni, V Pavone, S Palmieri, M Musso, ...
Hematological Oncology 40 (5), 1009-1019, 2022
Mandati: Governo Italiano
t (5; 12)(q31; p13)/ETV6:: ACSL6 and t (6; 9)(p23; q34)/DEK:: NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities
C Baldazzi, S Luatti, G Marzocchi, A Grassi, M Cavo, N Testoni
Cancer Genetics 262, 35-39, 2022
Mandati: Governo Italiano
OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading
M Martello, A Poletti, E Borsi, B Taurisano, V Solli, S Armuzzi, ...
Clinical Lymphoma Myeloma and Leukemia 21, S37, 2021
Mandati: Fondazione AIRC per la Ricerca sul Cancro
P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles
G Mazzocchetti, A Poletti, V Solli, E Borsi, M Martello, I Vigliotta, S Armuzzi, ...
Clinical Lymphoma Myeloma and Leukemia 21, S67, 2021
Mandati: Fondazione AIRC per la Ricerca sul Cancro
CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis
S De Santis, M Mancini, C Monaldi, S Bruno, F Castagnetti, G Gugliotta, ...
Clinical Lymphoma Myeloma and Leukemia 21, S329-S330, 2021
Mandati: Fondazione AIRC per la Ricerca sul Cancro
MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition
C Monaldi, M Mancini, S De Santis, S Bruno, M Rondoni, C Papayannidis, ...
Clinical Lymphoma Myeloma and Leukemia 21, S356-S357, 2021
Mandati: Fondazione AIRC per la Ricerca sul Cancro
MPN-204: Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis
C Monaldi, M Mancini, S De Santis, M Martelli, M Rondoni, ...
Clinical Lymphoma Myeloma and Leukemia 20, S334, 2020
Mandati: Fondazione AIRC per la Ricerca sul Cancro
Disponibili pubblicamente: 120
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863-2869, 2015
Mandati: US National Institutes of Health
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
Mandati: US National Institutes of Health
Proteasome inhibitors in multiple myeloma: 10 years later
P Moreau, PG Richardson, M Cavo, RZ Orlowski, JF San Miguel, ...
Blood, The Journal of the American Society of Hematology 120 (5), 947-959, 2012
Mandati: US National Institutes of Health
International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease
E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ...
Journal of clinical oncology 31 (18), 2347-2357, 2013
Mandati: US National Institutes of Health
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ...
Leukemia 27 (4), 780-791, 2013
Mandati: US National Institutes of Health, Government of Spain
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software